Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temsirolimus - Pfizer

Drug Profile

Temsirolimus - Pfizer

Alternative Names: CCI-779; Cell cycle inhibitor-779; NSC-683864; Torisel

Latest Information Update: 11 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Johann Wolfgang Goethe Universitatsklinikum; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; National Comprehensive Cancer Network; NCIC Clinical Trials Group; Pfizer; Wyeth
  • Class Antineoplastics; Macrolides
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Mantle-cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Renal cell carcinoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Glioblastoma; Glioma; Hodgkin's disease; Non-Hodgkin's lymphoma; Thyroid cancer
  • Phase I/II Follicular lymphoma; Head and neck cancer
  • No development reported Colorectal cancer; Lymphoma; Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Solid tumours
  • Discontinued Breast cancer; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 26 Feb 2019 Wyeth terminates a phase II trial in Hodgkin's lymphoma (Second-line therapy or greater) in USA due to lack of enrolment (IV) (NCT00838955)
  • 16 Jan 2019 Pfizer completes a phase I trial in Lymphoma and Solid tumors in Canada (NCT02343718)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, In adolescents, Recurrent, Second-line therapy or greater) in Canada (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top